BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: . Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. Liver Cancer 2015;4:85-95. [PMID: 26020031 DOI: 10.1159/000367730] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kudo M. Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm. Liver Cancer 2017;6:185-8. [PMID: 28626730 DOI: 10.1159/000462199] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
2 Leathers JS, Balderramo D, Prieto J, Diehl F, Gonzalez-ballerga E, Ferreiro MR, Carrera E, Barreyro F, Diaz-ferrer J, Singh D, Mattos AZ, Carrilho F, Debes JD. Sorafenib for Treatment of Hepatocellular Carcinoma: A Survival Analysis From the South American Liver Research Network. Journal of Clinical Gastroenterology 2019;53:464-9. [DOI: 10.1097/mcg.0000000000001085] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kudo M. Heterogeneity and Subclassification of Barcelona Clinic Liver Cancer Stage B. Liver Cancer 2016;5:91-6. [PMID: 27386427 DOI: 10.1159/000367768] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
4 Kwon J, Chun KS, Song IS, Kim SH, Han S. Long-term outcome of intraoperative radiofrequency ablation for hepatocellular carcinoma and its efficacy as a primary treatment. Ann Hepatobiliary Pancreat Surg 2020;24:24-32. [PMID: 32181425 DOI: 10.14701/ahbps.2020.24.1.24] [Reference Citation Analysis]
5 Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Ann Gastroenterol 2018;31:315-29. [PMID: 29720857 DOI: 10.20524/aog.2018.0245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Liang KH, Lai MW, Lin YH, Chu YD, Lin CL, Lin WR, Huang YH, Wang TH, Chien RN, Hu TH, Yeh CT. Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients. BMC Gastroenterol 2021;21:177. [PMID: 33865328 DOI: 10.1186/s12876-021-01761-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 He LL, Liu XL, Zhang S, Li MG, Wang XB, Jiang YY, Yang ZY. Independent risk factors for disease recurrence after surgery in patients with hepatitis B virus-related hepatocellular carcinoma ≤3 cm in diameter. Gastroenterol Rep (Oxf) 2019;7:250-7. [PMID: 31413831 DOI: 10.1093/gastro/goz009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bashir MR, Horowitz JM, Kamel IR, Arif-Tiwari H, Asrani SK, Chernyak V, Goldstein A, Grajo JR, Hindman NM, Kamaya A, McNamara MM, Porter KK, Solnes LB, Srivastava PK, Zaheer A, Carucci LR; Expert Panel on Gastrointestinal Imaging. ACR Appropriateness Criteria® Chronic Liver Disease. J Am Coll Radiol 2020;17:S70-80. [PMID: 32370979 DOI: 10.1016/j.jacr.2020.01.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Badawy A, Seo S, Toda R, Fuji H, Fukumitsu K, Taura K, Kaido T, Uemoto S. Different clinical risk scores for prediction of early mortality after liver resection for hepatocellular carcinoma: which is the best? ANZ J Surg 2019;89:1275-80. [PMID: 31389123 DOI: 10.1111/ans.15368] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer 2021;10:451-60. [PMID: 34721507 DOI: 10.1159/000516605] [Reference Citation Analysis]
11 Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, He Y, Swiatek-de Lange M, Morgenstern D, Chan HL. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. Hepatol Commun 2021. [PMID: 34796691 DOI: 10.1002/hep4.1847] [Reference Citation Analysis]
12 Takeda K, Tsurumaru Y, Yamamoto Y, Araki K, Kogure Y, Mori K, Nakagawa K, Shimizu T, Matsuda G, Niino H, Sekido H, Kobayashi S, Morimoto M, Kunisaki C, Endo I. Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report. Clin J Gastroenterol 2020;13:428-33. [PMID: 31970661 DOI: 10.1007/s12328-019-01077-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 109] [Article Influence: 17.7] [Reference Citation Analysis]
14 Cucchetti A, Vitale A. Personalized management of patients with very early hypovascular hepatocellular carcinoma. Liver Int 2018;38:415-6. [PMID: 29469211 DOI: 10.1111/liv.13699] [Reference Citation Analysis]
15 Tat Trung N, Duong DC, Tong HV, Hien TTT, Hoan PQ, Bang MH, Binh MT, Ky TD, Tung NL, Thinh NT, Sang VV, Thao LTP, Bock CT, Velavan TP, Meyer CG, Song LH, Toan NL. Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma. PLoS One 2018;13:e0196081. [PMID: 29672637 DOI: 10.1371/journal.pone.0196081] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
16 Takaya H, Namisaki T, Kitade M, Kaji K, Nakanishi K, Tsuji Y, Shimozato N, Moriya K, Seki K, Sawada Y, Saikawa S, Sato S, Kawaratani H, Akahane T, Noguchi R, Matsumoto M, Yoshiji H. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. BMC Gastroenterol. 2019;19:167. [PMID: 31638892 DOI: 10.1186/s12876-019-1082-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
17 Rosiak G, Podgórska J, Rosiak E, Cieszanowski A. CT/MRI LI-RADS v2017 - review of the guidelines. Pol J Radiol 2018;83:e355-65. [PMID: 30627260 DOI: 10.5114/pjr.2018.78391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
18 Pinna AD, Yang T, Mazzaferro V, De Carlis L, Zhou J, Roayaie S, Shen F, Sposito C, Cescon M, Di Sandro S, Yi-Feng H, Johnson P, Cucchetti A. Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma. Ann Surg 2018;268:868-75. [PMID: 30080736 DOI: 10.1097/SLA.0000000000002889] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 17.0] [Reference Citation Analysis]
19 Serra C, Cucchetti A, Felicani C, Mosconi C, De Cinque A, Golfieri R, Andreone P, Ercolani G, Maroni L, Ravaioli M, D'Errico A, Pinna AD, Cescon M. Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pretransplant Radiology. Liver Transpl 2019;25:88-97. [PMID: 30415500 DOI: 10.1002/lt.25381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
20 Yoh T, Seo S, Taura K, Iguchi K, Ogiso S, Fukumitsu K, Ishii T, Kaido T, Uemoto S. Surgery for Recurrent Hepatocellular Carcinoma: Achieving Long-term Survival. Ann Surg. 2019;. [PMID: 31058698 DOI: 10.1097/sla.0000000000003358] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
21 Chen Y, Yang Y, Li S, Lin M, Xie X, Shi H, Jiang Y, Zheng S, Shao H, Yang N, Lu M. Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients. Front Public Health 2022;9:784718. [DOI: 10.3389/fpubh.2021.784718] [Reference Citation Analysis]
22 Toyoda H, Hiraoka A, Olivares J, Al-Jarrah T, Devlin P, Kaneoka Y, Maeda A, Yopp AC, Parikh ND, Singal AG. Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31491-9. [PMID: 33295281 DOI: 10.1016/j.cgh.2020.10.033] [Reference Citation Analysis]
23 Jin H, Wang H, Li G, Hou Q, Wu W, Liu F. Risk factors for early postoperative recurrence in single and small hepatitis B virus-associated primary hepatocellular carcinoma. J Int Med Res 2020;48:300060520961260. [PMID: 33044114 DOI: 10.1177/0300060520961260] [Reference Citation Analysis]
24 Kudo M. Locoregional Therapy for Hepatocellular Carcinoma. Liver Cancer 2015;4:163-4. [PMID: 26674459 DOI: 10.1159/000367741] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
25 Cucchetti A, Serenari M. Efficacy of radiofrequency ablation of hepatocellular carcinoma prior to liver transplantation and the need for competing-risk analysis. Hepatobiliary Surg Nutr 2018;7:294-6. [PMID: 30221158 DOI: 10.21037/hbsn.2018.04.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 De Stefano F, Chacon E, Turcios L, Marti F, Gedaly R. Novel biomarkers in hepatocellular carcinoma. Dig Liver Dis. 2018;50:1115-1123. [PMID: 30217732 DOI: 10.1016/j.dld.2018.08.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
27 Terzi E, Salvatore V, Negrini G, Piscaglia R. Ongoing challenges in the diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2015;Nov 24; Epub ahead of print. [PMID: 26603785 DOI: 10.1586/17474124.2016.1124758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
28 Gentile I, Buonomo AR, Scotto R, Zappulo E, Carriero C, Piccirillo M, Izzo F, Rizzo M, Cerasuolo D, Borgia G, Cavalcanti E. Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection. In Vivo 2017;31:695-700. [PMID: 28652441 DOI: 10.21873/invivo.11115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
29 Braun M, Kuncman W, Teresiński L, Kupnicki P, Jesionek-Kupnicka D, Kordek R. Pure hepatocellular carcinoma originates from an ectopic liver nodule located in the pancreas. Contemp Oncol (Pozn) 2017;21:311-4. [PMID: 29416439 DOI: 10.5114/wo.2017.72403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
30 Kudo M, Morimoto M, Moriguchi M, Izumi N, Takayama T, Yoshiji H, Hino K, Oikawa T, Chiba T, Motomura K, Kato J, Yasuchika K, Ido A, Sato T, Nakashima D, Ueshima K, Ikeda M, Okusaka T, Tamura K, Furuse J. A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. Cancer Sci 2020;111:3759-69. [PMID: 32716114 DOI: 10.1111/cas.14582] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
31 Ohara M, Ogawa K, Suda G, Kimura M, Maehara O, Shimazaki T, Suzuki K, Nakamura A, Umemura M, Izumi T, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ohnishi S, Sakamoto N. L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis. Hepatol Commun. 2018;2:906-918. [PMID: 30094402 DOI: 10.1002/hep4.1207] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
32 Kudo M. Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Who Achieved Sustained Virological Response. Liver Cancer 2016;5:155-61. [PMID: 27493891 DOI: 10.1159/000443563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Ryu MR, Kang ES, Park HD. Performance evaluation of serum PIVKA-II measurement using HISCL-5000 and a method comparison of HISCL-5000, LUMIPULSE G1200, and ARCHITECT i2000. J Clin Lab Anal 2019;33:e22921. [PMID: 31131509 DOI: 10.1002/jcla.22921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol. 2017;52:494-503. [PMID: 27549242 DOI: 10.1007/s00535-016-1247-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]